10 Stocks With Crazy Gains

4. Tempus AI Inc. (NASDAQ:TEM)

Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in sealed contracts and achieving a revenue retention of around 126 percent last year.

At market close, the stock finished 4.51 percent at $69.26 apiece.

In a statement, Tempus AI Inc. (NASDAQ:TEM) said that it inked data agreements with 70 customers last year, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, as well as biotechnology companies namely Incyte, Servier, Aspera Biomedicines, and Whitehawk Therapeutics, among others.

“2025 was a record year for our Data and applications business—both from a revenue and TCV perspective,” said Tempus AI Inc. (NASDAQ:TEM) Chief Finance Officer Jim Rogers.

“Our engagement with life sciences companies has never been stronger, and our data business has never been better positioned, giving us tremendous visibility to continued growth in 2026 and beyond,” he added.

Tempus AI Inc. (NASDAQ:TEM) said that official data from its 2025 financial and operating performance have yet to be finalized, but said that it targets to announce the results in an earnings call in February 2026.